GLAXOSMITHKLINE PHARMA LT Latest Share Price (GLAXO)
TODAY IN ONE LINE
GLAXO slipped 0.4% on light volume, in line with Nifty's -0.3% move.
With a market cap of ₹47,942.76 Cr., it trades at a P/E of 44.89. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
GLAXOSMITHKLINE PHARMA LT flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 87.8% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 45.3%
- ●Healthy Operating MarginsOPM is structurally strong at 36.9%
- ●High Promoter HoldingPromoters hold 75.0% skin-in-the-game
- ●Steady Dividend YieldReliable 2.01% dividend yield
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest GLAXOSMITHKLINE PHARMA LT News
What changed recently?
Recent events, corporate actions, and announcements.
GLAXOSMITHKLINE PHARMA LT valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for GLAXOSMITHKLINE PHARMA LT, framed against the sector median so the premium or discount is obvious at a glance.
GLAXOSMITHKLINE PHARMA LT trades at a P/E of 44.89× and P/B of 21.14×, against the Healthcare sector median P/E of 46.02×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
GLAXOSMITHKLINE PHARMA LT technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for GLAXOSMITHKLINE PHARMA LT — derived from the latest tape, not yesterday's close.
GLAXOSMITHKLINE PHARMA LT last traded at ₹2,828.4 with an intraday range of ₹2,793.9–₹2,863.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2828.40| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 3002.50 | +174.10 | +6.16% |
| R3 | 2932.90 | +104.50 | +3.69% |
| R2 | 2898.20 | +69.80 | +2.47% |
| R1 | 2863.30 | +34.90 | +1.23% |
| PIVOT | 2828.60 | 0.20 | 0.01% |
| CURRENT | 2828.40 | — | — |
| S1 | 2793.70 | -34.70 | -1.23% |
| S2 | 2759.00 | -69.40 | -2.45% |
| S3 | 2724.10 | -104.30 | -3.69% |
| S4 | 2654.50 | -173.90 | -6.15% |
GLAXO is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹2793.9–₹2853.6
Trading Below opening range, showing Bearishness
GLAXOSMITHKLINE PHARMA LT financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for GLAXOSMITHKLINE PHARMA LT — consolidated or standalone — with margins, YoY growth and key ratios inline.
GLAXOSMITHKLINE PHARMA LT reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹47,942.76 Cr. and reported EPS of ₹14.00.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 3,749 | 3,822 ▲ 1.9% |
| Sales Growth YoY %Derived | 8.56% | 1.93% |
| Other Income | 146 | 145 ▼ 0.4% |
| Total Income | 3,895 | 3,967 ▲ 1.8% |
| 1,391 | 1,351 ▼ 2.9% | |
| Gross ProfitDerived | 2,358 | 2,471 ▲ 4.8% |
| Gross Margin %Derived | 62.90% | 64.65% |
| 1,181 | 1,161 ▼ 1.7% | |
| EBITDA (Operating Profit)Derived | 1,177 | 1,309 ▲ 11.2% |
| OPM %Derived | 31.40% | 34.26% |
| 73 | 90 ▲ 23.4% | |
| Profit Before Tax (PBT) | 1,260 | 1,406 ▲ 11.6% |
| 332 | 370 ▲ 11.4% | |
| Effective Tax %Derived | 26.38% | 26.32% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | 928 | 1,036 ▲ 11.7% |
| Net Profit (Owner's PAT)Derived | 928 | 1,036 ▲ 11.7% |
| Net Profit Margin %Derived | 24.74% | 27.11% |
| PAT Growth YoY %Derived | 57.23% | 11.69% |
| Earnings Per Share (EPS ₹) | 54.75 | 61.15 ▲ 11.7% |
| Diluted Shares Outstanding (Cr) | 17 | 17 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -3 | -8 ▼ 183.5% |
| Total Expenses (incl. D&A & Interest) | 2,635 | 2,561 ▼ 2.8% |
| Material Cost % of RevenueDerived | 13.33% | 11.41% |
| Employee Cost % of RevenueDerived | 15.46% | 15.89% |
| Other Cost % of RevenueDerived | 16.04% | 14.50% |
| Interest Coverage (x)Derived | 847.76x | 455.22x |
| Period | Mar 2018 | Mar 2019 | Sept 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sept 2022 | Mar 2023 | Mar 2024 | Sept 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,896 | 3,128 ▲ 8.0% | 1,670 ▼ 46.6% | 3,224 ▲ 93.1% | 3,199 ▼ 0.8% | 3,278 ▲ 2.5% | 1,662 ▼ 49.3% | 3,252 ▲ 95.7% | 3,454 ▲ 6.2% | 1,825 ▼ 47.1% | 3,749 ▲ 105.4% | 3,822 ▲ 1.9% | |
| Sales Growth YoY %Derived | — | 8.03% | — | 3.08% | -0.79% | 2.47% | — | -0.80% | 6.21% | — | 8.56% | 1.93% | |
| Other Income | 55 | 102 ▲ 87.6% | 47 ▼ 54.4% | 79 ▲ 69.2% | 111 ▲ 40.0% | 76 ▼ 31.5% | 50 ▼ 34.6% | 101 ▲ 103.0% | 123 ▲ 21.8% | 70 ▼ 42.8% | 146 ▲ 107.9% | 145 ▼ 0.4% | |
| Total Income | 2,950 | 3,230 ▲ 9.5% | 1,717 ▼ 46.9% | 3,303 ▲ 92.4% | 3,309 ▲ 0.2% | 3,354 ▲ 1.3% | 1,712 ▼ 49.0% | 3,352 ▲ 95.9% | 3,576 ▲ 6.7% | 1,896 ▼ 47.0% | 3,895 ▲ 105.5% | 3,967 ▲ 1.8% | |
1,241 | 1,358 ▲ 9.4% | 701 ▼ 48.4% | 1,308 ▲ 86.7% | 1,313 ▲ 0.4% | 1,356 ▲ 3.3% | 652 ▼ 51.9% | 1,285 ▲ 97.1% | 1,335 ▲ 3.9% | 680 ▼ 49.1% | 1,391 ▲ 104.6% | 1,351 ▼ 2.9% | ||
| Gross ProfitDerived | 1,654 | 1,770 ▲ 7.0% | 969 ▼ 45.2% | 1,917 ▲ 97.7% | 1,886 ▼ 1.6% | 1,922 ▲ 1.9% | 1,010 ▼ 47.4% | 1,967 ▲ 94.7% | 2,119 ▲ 7.7% | 1,146 ▼ 45.9% | 2,358 ▲ 105.9% | 2,471 ▲ 4.8% | |
| Gross Margin %Derived | 57.13% | 56.59% | 58.04% | 59.44% | 58.96% | 58.63% | 60.77% | 60.49% | 61.36% | 62.76% | 62.90% | 64.65% | |
1,149 | 1,169 ▲ 1.8% | 610 ▼ 47.8% | 1,259 ▲ 106.4% | 1,191 ▼ 5.4% | 1,160 ▼ 2.6% | 604 ▼ 47.9% | 1,163 ▲ 92.4% | 1,210 ▲ 4.1% | 593 ▼ 51.0% | 1,181 ▲ 99.0% | 1,161 ▼ 1.7% | ||
| EBITDA (Operating Profit)Derived | 506 | 601 ▲ 18.8% | 359 ▼ 40.2% | 657 ▲ 82.9% | 695 ▲ 5.8% | 762 ▲ 9.6% | 406 ▼ 46.7% | 804 ▲ 98.2% | 909 ▲ 13.0% | 552 ▼ 39.2% | 1,177 ▲ 113.2% | 1,309 ▲ 11.2% | |
| OPM %Derived | 17.47% | 19.21% | 21.52% | 20.38% | 21.74% | 23.24% | 24.42% | 24.73% | 26.31% | 30.25% | 31.40% | 34.26% | |
56 | 78 ▲ 39.0% | 445 ▲ 471.4% | -252 ▼ 156.8% | -90 ▲ 64.4% | 82 ▲ 191.1% | 33 ▼ 59.3% | 67 ▲ 100.3% | -72 ▼ 208.3% | 39 ▲ 153.5% | 73 ▲ 88.6% | 90 ▲ 23.4% | ||
| Profit Before Tax (PBT) | 540 | 683 ▲ 26.4% | 764 ▲ 11.8% | 306 ▼ 60.0% | 551 ▲ 80.1% | 779 ▲ 41.5% | 422 ▼ 45.8% | 836 ▲ 98.1% | 816 ▼ 2.4% | 593 ▼ 27.3% | 1,260 ▲ 112.4% | 1,406 ▲ 11.6% | |
189 | 237 ▲ 25.4% | 147 ▼ 37.9% | 213 ▲ 44.4% | 192 ▼ 9.5% | 398 ▲ 107.1% | 113 ▼ 71.7% | 229 ▲ 103.3% | 226 ▼ 1.1% | 158 ▼ 30.0% | 332 ▲ 109.8% | 370 ▲ 11.4% | ||
| Effective Tax %Derived | 35.05% | 34.76% | 19.28% | 69.52% | 34.94% | 51.12% | 26.65% | 27.35% | 27.72% | 26.70% | 26.38% | 26.32% | |
| Profit/Loss from Discontinued Ops | — | — | — | — | — | 1,314 | 3 ▼ 99.8% | 3 ▲ 0.0% | — ▼ 100.0% | — | — | — | |
| Total Profit for Period | 351 | 445 ▲ 27.0% | 616 ▲ 38.4% | 93 ▼ 84.9% | 358 ▲ 284.3% | 381 ▲ 6.3% | 313 ▼ 17.9% | 611 ▲ 95.3% | 590 ▼ 3.4% | 435 ▼ 26.3% | 928 ▲ 113.3% | 1,036 ▲ 11.7% | |
| Net Profit (Owner's PAT)Derived | 351 | 445 ▲ 27.0% | 616 ▲ 38.4% | 93 ▼ 84.9% | 358 ▲ 284.3% | 381 ▲ 6.3% | 313 ▼ 17.9% | 611 ▲ 95.3% | 590 ▼ 3.4% | 435 ▼ 26.3% | 928 ▲ 113.3% | 1,036 ▲ 11.7% | |
| Net Profit Margin %Derived | 12.11% | 14.24% | 36.90% | 2.89% | 11.20% | 11.62% | 18.82% | 18.78% | 17.08% | 23.82% | 24.74% | 27.11% | |
| PAT Growth YoY %Derived | — | 26.99% | — | -79.07% | 284.28% | 6.32% | — | 60.38% | -3.39% | — | 57.23% | 11.69% | |
| Earnings Per Share (EPS ₹) | 20.70 | 26.29 ▲ 27.0% | 36.38 ▲ 38.4% | 5.50 ▼ 84.9% | 21.14 ▲ 284.4% | 100.04 ▲ 373.2% | 18.46 ▼ 81.5% | 36.05 ▲ 95.3% | 34.83 ▼ 3.4% | 25.67 ▼ 26.3% | 54.75 ▲ 113.3% | 61.15 ▲ 11.7% | |
| Diluted Shares Outstanding (Cr) | 17 | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | 17 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 6 | -5 ▼ 198.2% | -2 ▲ 63.2% | -4 ▼ 96.9% | -2 ▲ 48.5% | -2 ▲ 9.8% | 4 ▲ 310.3% | -6 ▼ 255.3% | -4 ▲ 31.0% | — ▲ 100.0% | -3 | -8 ▼ 183.5% | |
| Total Expenses (incl. D&A & Interest) | 2,410 | 2,548 ▲ 5.7% | 1,354 ▼ 46.8% | 2,998 ▲ 121.3% | 2,759 ▼ 8.0% | 2,575 ▼ 6.7% | 1,289 ▼ 49.9% | 2,516 ▲ 95.1% | 2,760 ▲ 9.7% | 1,307 ▼ 52.6% | 2,635 ▲ 101.6% | 2,561 ▼ 2.8% | |
| Material Cost % of RevenueDerived | 17.64% | 21.95% | 15.78% | 14.71% | 14.76% | 18.64% | 17.23% | 13.15% | 15.79% | 15.73% | 13.33% | 11.41% | |
| Employee Cost % of RevenueDerived | 18.08% | 17.17% | 17.38% | 19.49% | 19.22% | 18.62% | 17.64% | 18.30% | 18.08% | 16.54% | 15.46% | 15.89% | |
| Other Cost % of RevenueDerived | 21.59% | 20.21% | 19.15% | 19.56% | 18.01% | 16.77% | 18.71% | 17.45% | 16.97% | 15.96% | 16.04% | 14.50% | |
| Interest Coverage (x)Derived | 2,462.21x | 1,004.00x | 171.64x | 90.69x | 174.52x | 346.85x | 349.22x | 408.02x | 466.12x | 810.91x | 847.76x | 455.22x |
GLAXOSMITHKLINE PHARMA LT segment analysis : revenue and profit mix.
Disclosed business segments at GLAXOSMITHKLINE PHARMA LT with their share of revenue and profit, switchable between consolidated and standalone reporting.
GLAXOSMITHKLINE PHARMA LT discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for GLAXOSMITHKLINE PHARMA LT.
Our AI distills the core fundamental drivers supporting GLAXOSMITHKLINE PHARMA LT, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
GLAXOSMITHKLINE PHARMA LT's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
ROE 45.15% and ROCE 87.39% substantially exceed pharmaceutical peer averages consistently.
Operating margin 32.77% demonstrates exceptional pricing power and cost efficiency.
Net profit margin 27.21% ranks among highest in Indian pharmaceutical sector.
Negligible debt at ₹0.00 LCr with D/E ratio 0.0000 ensures financial fortress.
Promoter holding 75% signals strong long-term commitment and governance alignment.
Key Risks.
Latest quarterly EPS grew 5.70% YoY despite revenue headwinds, modest momentum.
Quarterly sales declined 1.49% YoY indicating near-term demand softness.
P/E ratio 39.69x elevated versus peer median, signals valuation premium.
Price-to-book 22.07x suggests limited margin of safety for new investors.
Payout ratio 161.69% exceeds earnings, unsustainable dividend structure long-term.
Flip Conditions.
Valuation risk. a P/E above 58 (~1.3× the sector multiple of 46.0) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 40% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 1.00%.
GLAXOSMITHKLINE PHARMA LT peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — GLAXOSMITHKLINE PHARMA LT is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
GLAXOSMITHKLINE PHARMA LT chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for GLAXOSMITHKLINE PHARMA LT — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
GLAXOSMITHKLINE PHARMA LT delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for GLAXOSMITHKLINE PHARMA LT over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in GLAXOSMITHKLINE PHARMA LT stood at 42.4% of traded volume, against a 20-day average of 50.8%.
GLAXOSMITHKLINE PHARMA LT announcements: results, concalls, ratings, M&A.
Filings GLAXOSMITHKLINE PHARMA LT sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
GLAXOSMITHKLINE PHARMA LT files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 172 documents below.
General Updates
GlaxoSmithKline PharmCorrigendum to the Notice of Postal Ballot dated August 3, 2026 aceuticals Limited has informed the Exchange about General…
Shareholders meeting
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot
Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
General Updates
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about General Updates
Copy of Newspaper Publication
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
GLAXOSMITHKLINE PHARMA LT dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue GLAXOSMITHKLINE PHARMA LT has declared, sequenced by announce and record date.
GLAXOSMITHKLINE PHARMA LT corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About GLAXOSMITHKLINE PHARMA LT: business, sector, key facts.
What GLAXOSMITHKLINE PHARMA LT does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
GLAXOSMITHKLINE PHARMA LT operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: GLAXO, BSE: 500660.
GlaxoSmithKline Pharmaceuticals Limited (GSK) is a major pharmaceutical company with a global presence, including significant operations in India. Its core business revolves around the manufacturing, distribution, and trading of a wide range of pharmaceutical products. The company's history stretches back to 1924, with its current name adopted in 2001. GSK's headquarters are located in Mumbai, India.
A substantial portion of GSK's business focuses on vaccines. Their portfolio includes Infanrix Hexa (for multiple infant diseases), Synflorix (pneumococcal diseases), Havrix (Hepatitis A), Menveo (meningococcal disease), Boostrix (diphtheria, tetanus, and pertussis), Fluarix Tetra (influenza), Varilrix (varicella), and Shingrix (herpes zoster). This extensive vaccine range caters to various age groups and disease preventions, establishing GSK as a key player in the global vaccine market.
Beyond vaccines, GSK offers a diverse portfolio of specialty medicines. Key examples include NUCALA, used to treat severe eosinophilic conditions like asthma, and TRELEGY ELLIPTA, a treatment for chronic obstructive pulmonary disease (COPD). These specialty medications target specific, often chronic, conditions, reflecting GSK's commitment to developing advanced therapies.
GSK also provides a broad selection of general medicines. This includes antibiotics like AUGMENTIN and CEFTUM for bacterial infections, various formulations for mineral and vitamin deficiencies (CobadexCZS, CCM), pain relievers (CALPOL), treatments for hypothyroidism (ELTROXIN), skin creams and ointments (Flutivate, Tenovate, BETNOVATE, PHYSIOGEL, NEOSPORIN, T-BACT) addressing a wide range of dermatological needs. This segment underscores GSK's commitment to providing accessible and widely used treatments for common ailments.
In summary, GlaxoSmithKline Pharmaceuticals Limited operates across multiple sectors of the pharmaceutical industry, offering a comprehensive range of vaccines, specialty medicines targeting complex conditions, and a large selection of general medicines for everyday health concerns. This diversified approach positions GSK as a significant player in the global pharmaceutical market.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about GLAXOSMITHKLINE PHARMA LT (GLAXO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of GLAXOSMITHKLINE PHARMA LT (GLAXO)?
The current share price of GLAXOSMITHKLINE PHARMA LT (GLAXO) is ₹2,828.40. Today, the stock has declined by ₹12.50 (0.44%), trading in a range of ₹2,793.90 to ₹2,863.50. The stock opened at ₹2,840.90 with a trading volume of 38,428 shares.
02Is GLAXOSMITHKLINE PHARMA LT stock a good investment for long-term?
GLAXOSMITHKLINE PHARMA LT can be considered for long-term investment based on several factors. The company has a market capitalization of ₹47,942.76 Cr., P/E ratio of 44.89, ROE of 45.34%, and ROCE of 87.77%. The dividend yield stands at 2.01%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of GLAXOSMITHKLINE PHARMA LT stock?
The 52-week high price of GLAXOSMITHKLINE PHARMA LT (GLAXO) is ₹3,120.70, while the 52-week low is ₹2,088.10. Currently trading at ₹2,828.40, the stock is 35.45% above its 52-week low and 9.37% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy GLAXOSMITHKLINE PHARMA LT stock at the current price?
Whether to buy GLAXOSMITHKLINE PHARMA LT stock at ₹2,828.40 depends on multiple factors. The stock is currently trading with a P/E ratio of 44.89 and P/B ratio of 21.14. Today's performance shows a loss of 0.44%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of GLAXOSMITHKLINE PHARMA LT and when is the next dividend?
GLAXOSMITHKLINE PHARMA LT offers a dividend yield of 2.01%, which means for every ₹100 invested at the current price of ₹2,828.40, you can expect to receive approximately ₹2.01 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of GLAXOSMITHKLINE PHARMA LT?
GLAXOSMITHKLINE PHARMA LT's key financial metrics include: P/E Ratio: 44.89, P/B Ratio: 21.14, ROE: 45.34%, ROCE: 87.77%, Dividend Yield: 2.01%, EPS: ₹14.00, Book Value: ₹134.86, and Debt-to-Equity: 0. The company's market cap stands at ₹47,942.76 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is GLAXOSMITHKLINE PHARMA LT stock performing today in the market?
GLAXOSMITHKLINE PHARMA LT stock opened at ₹2,840.90 and is currently trading at ₹2,828.40, showing a decline of ₹12.50 (0.44%). The intraday high is ₹2,863.50 and low is ₹2,793.90. The trading volume stands at 38,428 shares, indicating moderate market participation today.
08What is the P/E ratio of GLAXOSMITHKLINE PHARMA LT and what does it indicate?
GLAXOSMITHKLINE PHARMA LT has a Price-to-Earnings (P/E) ratio of 44.89, which means investors are willing to pay 44.89 for every ₹1 of earnings. With an EPS of ₹14.00, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about GLAXOSMITHKLINE PHARMA LT (GLAXO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.